FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to new derivatives of nitroimidazole of formula (I), as well as to a pharmaceutical composition based on them and use for the manufacture of a medicament for the treatment of diseases caused by Mycobacterium tuberculosis. .
EFFECT: technical result: new compounds with inhibitory activity against Mycobacterium tuberculosis, which, in addition, have high solubility and permeability.
11 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
BICYCLIC NITROIMIDAZOLES COVALENTLY CONNECTED TO REPLACED PHENYLOXAZOLYDINONES | 2009 |
|
RU2504547C2 |
RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | 2016 |
|
RU2697703C2 |
NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND USE THEREOF | 2010 |
|
RU2540860C2 |
COMPOUND BASED ON DIHYDRONAPTHYRIDINONE, METHOD OF ITS OBTAINING, AND ITS USE IN MEDICINE | 2021 |
|
RU2809869C1 |
TRKA KINASE INHIBITORS, COMPOSITIONS BASED THEREON AND METHODS | 2015 |
|
RU2672583C2 |
PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
BICYCLIC DERIVATIVES | 2019 |
|
RU2794894C2 |
IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
Authors
Dates
2018-12-21—Published
2016-01-28—Filed